Toll Free: 1-888-928-9744

Visceral Pain - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Visceral Pain - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Visceral Pain - Pipeline Review, H1 2017, provides an overview of the Visceral Pain (Central Nervous System) pipeline landscape.

Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or NSAIDs and pain modifiers such as tricyclic antidepressants or anticonvulsants. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Visceral Pain - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Visceral Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Visceral Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, IND/CTA Filed and Preclinical stages are 1, 1 and 13 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Visceral Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Visceral Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Visceral Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Visceral Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Visceral Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Visceral Pain (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Visceral Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Visceral Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Visceral Pain - Overview Visceral Pain - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Visceral Pain - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Visceral Pain - Companies Involved in Therapeutics Development Addex Therapeutics Ltd Anavex Life Sciences Corp Astellas Pharma Inc BELLUS Health Inc Chromocell Corp Eli Lilly and Company GIcare Pharma Inc Grunenthal GmbH Medestea Research & Production SpA Neurim Pharmaceuticals Ltd Pfizer Inc Visceral Pain - Drug Profiles ADX-71441 - Drug Profile Product Description Mechanism Of Action R&D Progress ADX-71743 - Drug Profile Product Description Mechanism Of Action R&D Progress ANAVEX-1066 - Drug Profile Product Description Mechanism Of Action R&D Progress ASP-7663 - Drug Profile Product Description Mechanism Of Action R&D Progress BLU-5937 - Drug Profile Product Description Mechanism Of Action R&D Progress CC-8464 - Drug Profile Product Description Mechanism Of Action R&D Progress GIC-1002 - Drug Profile Product Description Mechanism Of Action R&D Progress HS-665 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile Product Description Mechanism Of Action R&D Progress NeuP-12 - Drug Profile Product Description Mechanism Of Action R&D Progress NXN-677 - Drug Profile Product Description Mechanism Of Action R&D Progress piromelatine - Drug Profile Product Description Mechanism Of Action R&D Progress RO-656570 - Drug Profile Product Description Mechanism Of Action R&D Progress SBFI-26 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit Autotaxin for Central Nervous System and Gastrointestinal Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides to Agonize OXTR for Abdominal Pain and Chronic Visceral Pain - Drug Profile Product Description Mechanism Of Action R&D Progress URB-937 - Drug Profile Product Description Mechanism Of Action R&D Progress WITH-1101 - Drug Profile Product Description Mechanism Of Action R&D Progress Visceral Pain - Dormant Projects Visceral Pain - Discontinued Products Visceral Pain - Product Development Milestones Featured News & Press Releases Nov 14, 2016: Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic in Animal Models of Neuropathic and Visceral Pain Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Visceral Pain, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Visceral Pain - Pipeline by Addex Therapeutics Ltd, H1 2017 Visceral Pain - Pipeline by Anavex Life Sciences Corp, H1 2017 Visceral Pain - Pipeline by Astellas Pharma Inc, H1 2017 Visceral Pain - Pipeline by BELLUS Health Inc, H1 2017 Visceral Pain - Pipeline by Chromocell Corp, H1 2017 Visceral Pain - Pipeline by Eli Lilly and Company, H1 2017 Visceral Pain - Pipeline by GIcare Pharma Inc, H1 2017 Visceral Pain - Pipeline by Grunenthal GmbH, H1 2017 Visceral Pain - Pipeline by Medestea Research & Production SpA, H1 2017 Visceral Pain - Pipeline by Neurim Pharmaceuticals Ltd, H1 2017 Visceral Pain - Pipeline by Pfizer Inc, H1 2017 Visceral Pain - Dormant Projects, H1 2017 Visceral Pain - Dormant Projects, H1 2017 (Contd..1), H1 2017 Visceral Pain - Discontinued Products, H1 2017



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify